THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in…
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30…
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapiesHONG…
Expanding access to fast, accurate syphilis testing to support Australia’s public health response. iStatis Syphilis Antibody Test iStatis Syphilis Antibody…
AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO…
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer…
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer…
Acquisition aims to strengthen the EY organization's Veeva Centers of Excellence, expanding clinical, regulatory and commercial services capabilities for global pharma and…
Cognixion's non-invasive brain-computer interface powered by conversational AI, has been honored by TIME Magazine as one of the Best Inventions…
objectiveFIELD is the first and only truly objective perimeter FDA 510(k) cleared to assess visual field abnormalitiesIrvine, California--(Newsfile Corp. -…